NVCR News and Press, NovoCure Limited From 08/13/21

Novocure (NASDAQ: NVCR) disappointed investors with its second-quarter results announced on July 29. However, the company could have better news on the way. In this Motley Fool Live video recorded on Aug. 4 , Motley Fool contributors Keith Speights and Brian Orelli discuss w...

Shares of Novocure (NASDAQ: NVCR) slid this week in response to a disappointing second-quarter earnings report. Investors aren't happy about the slower-than-anticipated rollout of the company's Tumor Treating Fields, or TTF, therapy. The healthcare stock finished the week down 18.7%...

The following slide deck was published by NovoCure Limited in conjunction with their 2021 Q2 earnings call. For further details see: NovoCure Limited 2021 Q2 - Results - Earnings Call Presentation

Quarterly earnings aren't providing much of a cure for Novocure (NASDAQ: NVCR) . The company, which concentrates on novel cancer-fighting solutions, saw its stock dive by almost 10% on Thursday following the publication of its latest set of results. In Q2, Novocure took in $...

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2021 Earnings Call Jul 29, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2021 Earnings Call Transcript

NovoCure Limited (NVCR) Q2 2021 Earnings Conference Call July 29, 2021 08:00 AM ET Company Participants Ingrid Goldberg - Vice President Finance & Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Uri Weinbe...

NovoCure (NASDAQ:NVCR) shares slide more than 4% premarket after the company posted second-quarter results that missed Wall Street estimates, hurt my a rise in research and development expenses during the period. Quarterly revenue rose 15% to $133.5M, but fell short of analysts' ave...

NovoCure (NASDAQ:NVCR): Q2 GAAP EPS of -$0.14 misses by $0.15. Revenue of $133.5M (+15.2% Y/Y) misses by $8.34M. Quarterly net revenues of $133.5 million, presenting 15% growth versus the second quarter of 2020 with 79% gross margin. There were 3,487 active patients at June 30, 2021, represen...

Quarterly net revenues of $133.5 million, presenting 15% growth versus the second quarter of 2020 with 79% gross margin Invested record $50 million in research and development initiatives across brain, thoracic and abdominal programs Novocure (NASDAQ: NVCR) today rep...

Awards totaling more than $2 million aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies Novocure (NASDAQ: NVCR) today announced the recipients of the 3rd Annual AACR-Novoc...